Clinical trials: Venous
Mixed Venous Oxygen Saturation, Tissue Oxygenation
Validation of Mixed Venous Blood Oxygen Saturation Obtained With a Novel Mathematical Equation
The purpose of this study is to test a new way to measure the oxygen level in the mixed venous blood system (the system that carries blood collected from all over the body to the heart), which is a very important monitoring tool…
- Trial name
- NCT00783952
- Testing
- Cerebral/Somatic Tissue Oximeter device, Pulmonary artery catheter
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts General Hospital
Deep Vein Thrombosis, Pulmonary Embolism
Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism
Design: U.S.-based, single-center, randomized placebo-controlled trial. Brief Treatment Description: Low-intensity apixaban (2.5mg twice daily) for extended-duration secondary prevention of VTE after initial treatment for…
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
- Trial name
- HI-PRO (NCT04168203)
- Testing
- Apixaban 2.5 MG
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Brigham and Women's Hospital
Deep Vein Thrombosis
SCD Use to Prevent Deep Venous Thrombosis (DVT) in Patients With PICC Lines
The purpose of this study is to see if a compression device on the arm where a peripherally inserted central catheter (PICC) line has been inserted can prevent the formation of a blood clot around the PICC line.
- Trial name
- NCT01670188
- Testing
- Pneumatic SCD - VenaFlow System (DJO Global)
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Mayo Clinic
Hemorrhage
Reversal Dabigatran Anticoagulant Effect With Idarucizumab
The trial objective is to demonstrate the safety of idarucizumab, as assessed by the occurence of patients with drug related adverse events (including immune reactions) and all-cause mortality in paediatric venous thromboembolism…
- Trial name
- NCT02815670
- Testing
- Idarucizumab
- Where
- 2 sites in Russia
- Volunteers
- 1 people
- Sponsor
- Boehringer Ingelheim
Chronic Venous Insufficiency
VAP-PRO-C6. Effectiveness and Tolerability of Venoactive Drugs in Combination Therapy in Patients With CVD (CEAP C6)
The VAP-PRO-C6 is a Russian multicenter observational program to be implemented at the routine visits and assessments. The program will include patients with chronic venous disease of CEAP classes C6.
- Trial name
- VAP-PRO-C6 (NCT04757766)
- Testing
- in daily everyday routine practice
- Where
- Russia
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Servier Russia
Venous Thromboembolism
Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT
Subcutaneous enoxaparin is currently the gold standard for VTE chemoprophylaxis. However, the efficacy of chemoprophylaxis with subcutaneous enoxaparin is affected by patient-level factors, thus, resulting in VTE events despite…
- Trial name
- NCT04504318
- Testing
- Apixaban 2.5 MG Oral Tablet, Enoxaparin 40Mg/0.4mL Prefilled Syringe
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Stanford University
Thromboembolism, Arthroplasty, Replacement, Hip
Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery
The objective of this study is to determine the comparative efficacy and safety of two oral regimens of dabigatran etexilate, compared to a standard subcutaneous regimen of enoxaparin, in prevention of venous thromboembolism in…
- Trial name
- NCT00168818
- Testing
- dabigatran etexilate, enoxaparin
- Where
- 116 sites in Australia, Austria and 14 more
- Volunteers
- 3,494 people
- Sponsor
- Boehringer Ingelheim
Catheter-Associated Infections, Catheter-Related Infections
Safety and Effectiveness of Novel Nitroglycerin Based Catheter Lock Solution
The objective of this Phase I/II pilot study is to evaluate the safety and effectiveness of a non- antibiotic chelator based lock solution that contains nitroglycerin in combination with sodium citrate and ethanol (NiCE lock…
- Trial name
- NCT02577718
- Testing
- Nitroglycerin-citrate-ethanol (NiCE)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novel Anti-Infective Technologies, LLC
Bloodstream Infection
Ethanol Locks for the Treatment of Central Venous Line Infections
Ethanol Locks as an Adjunct Treatment for Central Venous Line Infections Purpose To evaluate the effectiveness of a 70% ethanol lock solution when used as an adjunct therapy with antibiotics to treat central venous line…
- Trial name
- NCT00680459
- Testing
- 70% ethanol, heparin flush solution
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Baystate Medical Center
Varicose Veins
The Long-term Value of Preoperative Duplex Before Surgery for Varicose Veins
Duplex imaging is costly and time-consuming, but is used increasingly for preoperative evaluation of varicose veins. Its value in terms of the long-term results of surgery is not clear.
- Trial name
- NCT01195623
- Testing
- preoperative duplex examination, Preoperative duplex
- Where
- Sweden
- Volunteers
- 293 people
- Sponsor
- Uppsala University Hospital
Coronavirus Disease 2019 (COVID-19)
A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection
The purpose of this study is to evaluate whether rivaroxaban reduces the risk of a composite endpoint of major venous and arterial thrombotic events, all-cause hospitalization, and all-cause mortality compared with placebo in…
- Trial name
- PREVENT-HD (NCT04508023)
- Testing
- Rivaroxaban, Standard of Care (SOC)
- Where
- 17 sites in United States
- Volunteers
- 1,284 people
- Sponsor
- Janssen Research & Development, LLC
Thromboembolism
Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates
The purpose of this study is to find out whether rivaroxaban is safe and effective to use in children age newborn to less than 6 months and how long it stays in the body and how it is used in the body.
- Trial name
- Einstein Jr (NCT02564718)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 9 sites in Austria, France and 5 more
- Volunteers
- 10 people
- Sponsor
- Bayer
Burns, Trauma
Split Thickness Donor Site Healing With MIST Study
Subjects requiring skin grafting due to burns, trauma, or chronic venous ulcers with split thickness donor sites expected to be between 20 and 200 square cm will be consecutively screened for study eligibility.
- Conditions
- Burns, Trauma, Venous Ulcers
- Trial name
- NCT01214980
- Testing
- MIST Therapy, Standard of care
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Celleration, Inc.
Macular Edema, Retinal Vein Occlusion
A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema Secondary to Retinal Vein Occlusion (RVO)
This study will evaluate the relationship between time since onset of macular oedema symptoms and the achievement of vision gain in patients prescribed OZURDEX®.
- Trial name
- NCT01571557
- Testing
- dexamethasone 700 ug intravitreal implant
- Where
- Germany
- Volunteers
- 573 people
- Sponsor
- Allergan
Deep Vein Thrombosis, Venous Thromboembolism
Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study
This is the first evaluation of edoxaban in pediatric subjects. In this Phase 1 study, a single dose of edoxaban will be given to pediatric subjects who require anticoagulant therapy to see what the body does to the drug…
- Trial name
- NCT02303431
- Testing
- Edoxaban low dose, Edoxaban high dose
- Where
- 35 sites in United States, Canada and 7 more
- Volunteers
- 66 people
- Sponsor
- Daiichi Sankyo
Deep Vein Thrombosis (DVT), Blood Clots
Below Knee DVT Study
Hospitalized patients are at risk of developing blood clots in the legs (Deep Vein Thrombosis or DVT), which can lead to death if those clots break off and migrate to the lungs.
- Trial name
- NCT03805672
- Testing
- Low Dose Enoxaparin, High Dose Enoxaparin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Oregon Health and Science University
Arthroplasty, Replacement, Hip, Thrombosis
Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement
Patients who undergo total hip replacement surgery are at greater risk of getting deep vein thrombosis (blood clots). This study evaluates the safety, tolerability and effectiveness of the study drug, DU-176b, in reducing the…
- Trial name
- NCT00107900
- Testing
- DU-176b
- Where
- United States
- Volunteers
- 606 people
- Sponsor
- Daiichi Sankyo
Vascular Access Complication, Ultrasound Therapy; Complications
Superior Venous Access, Midline vs Ultrasound IVs
Obtaining intravenous access (IVA) is the most common procedure performed in the emergency department (ED). Placement of IVA allows for blood work and delivery of intravenous fluids and medications.
- Trial name
- NCT03440944
- Testing
- Ultrasound Guided Peripheral IV Catheter, Midline Catheter
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Boston Medical Center
Obesity, Obesity, Morbid
Comparing Anti-XA Levels in Post-Cesarean Patients Undergoing Enoxaparin Thromboprophylaxis
Pregnant and recently postpartum women are at significantly higher risk of developing a blood clot in their arms or legs known as a deep venous thrombosis (DVT) and/or a blood clot in their lungs known as a pulmonary embolism…
- Conditions
- Obesity, Obesity, Morbid, Pregnancy, Complications; Cesarean Section
- Trial name
- NCT02070237
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- MemorialCare Health System
Arthroplasty, Replacement, Knee, Thromboembolism
Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement
To determine the comparative efficacy and safety of two different doses (75mg day 1 followed by 150 mg day 2-completion, and 110 mg day 1 followed by 220 mg day 2-completion) of dabigatran administered orally (capsules), compared…
- Trial name
- NCT00152971
- Testing
- Dabigatran Dose 1 - day 2 to completion, Dabigatran Dose 1 - day 1, Dabigatran Dose 2 - day 2 to completion
- Where
- 94 sites in United States, Canada and 2 more
- Volunteers
- 2,615 people
- Sponsor
- Boehringer Ingelheim